Stephen Machatha - 28 Feb 2023 Form 4 Insider Report for Aldeyra Therapeutics, Inc. (ALDX)

Role
Chief Development Officer
Signature
/s/ Stephen Machatha
Issuer symbol
ALDX
Transactions as of
28 Feb 2023
Net transactions value
$0
Form type
4
Filing time
02 Mar 2023, 15:27:10 UTC
Previous filing
19 Jul 2022
Next filing
12 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALDX Stock Option (right to buy) Award $0 +220,258 $0.000000 220,258 28 Feb 2023 Common Stock 220,258 $6.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2023.